干扰素λ3在慢性乙型肝炎患者血清中的表达及临床意义

段元丽; 管世鹤; 杨凯; 陈礼文; 张浩; 王秀; 潘正兰; 侯舒文; 王兆飞

doi:10.3969/j.issn.1001-5256.2019.02.014

干扰素λ3在慢性乙型肝炎患者血清中的表达及临床意义

DOI: 10.3969/j.issn.1001-5256.2019.02.014

安徽医科大学第二附属医院检验科

基金项目:

安徽省科技厅重点研究与开发计划项目(1804h08020236)；安徽省高校自然科学研究项目(KJ2018A0206)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1591
- HTML全文浏览量: 32
- PDF下载量: 310
- 被引次数: 0
出版历程
- 出版日期: 2019-02-20

Serum level of interferon-λ3 in patients with chronic hepatitis B and its clinical significance

Department of Clinical Laboratory, The Second Affiliated Hospital of Anhui Medical University

Research funding:

摘要

摘要:
目的了解慢性乙型肝炎患者血清IFNλ3水平,探究其临床意义及其与核苷和核苷酸类药物治疗的关系。方法选取2017年1月-2018年5月在安徽医科大学第二附属医院就诊的慢性乙型肝炎患者119例,收集同期HBsAg阴性的22例健康体检者作为健康对照。采用ELISA法检测血清中IFNλ3的表达水平,比较慢性乙型肝炎患者与健康人血清IFNλ3水平差异,分析慢性乙型肝炎患者血清IFNλ3水平与HBeAg的关系,观察不同核苷和核苷酸类药物治疗慢性乙型肝炎患者的血清IFNλ3水平,以及核苷和核苷酸类药物对外周血单个核细胞培养上清中IFNλ3水平的影响。满足正态性和方差齐性的计量资料多组间比较采用方差分析;对非正态或方差不齐的计量资料,两组比较采用Wilcoxon秩和检验,多组比较采用Kruskal-Wallis H检验,进一步两两比较采用Nemenyi法检验。相关性分析用Spearman相关性分析法。结果慢性乙型肝炎患者血清IFNλ3水平明显低于健康对照组[14. 7（5. 9～28. 5） pg/ml vs 76. 1（39. 4～112. 0） pg/ml,Z=-10. 114,P <0. ...
- 肝炎,乙型,慢性 /
- 干扰素类
Abstract:
Objective To investigate the serum level of interferon-λ3 ( IFN-λ3) and its clinical significance in patients with chronic hepatitis B ( CHB) , as well as its association with nucleos ( t) ide analogue ( NA) treatment. Methods A total of 119 CHB patients who were treated in The Second Affiliated Hospital of Anhui Medical University from January 2017 to May 2018 were enrolled, and 22 HBsAg-negative individuals who underwent physical examination were enrolled as healthy control group. ELISA was used to measure the serum level of IFN-λ3, which was compared between CHB patients and healthy individuals. The association between serum IFN-λ3 level and HBeAg in CHB patients was analyzed; serum IFN-λ3 level was compared between the patients treated with different NAs; the influence of NAs on the level of IFN-λ3 in the supernatant of peripheral blood mononuclear cells ( PBMCs) was analyzed. An analysis of variance was used for comparison of normally distributed continuous data with homogeneity of variance between multiple groups; the Wilcoxon rank-sum test was used for comparison of non-normally distributed continuous data or continuous data with heterogeneity of variance between two groups, the Kruskal-Wallis H test was used for comparison between multiple groups, and the Nemenyi test was used for further comparison between two groups. A Spearman correlation analysis was also performed. Results The CHB group had a significantly lower serum IFN-λ3 level than the healthy control group [14. 7 ( 5. 9-28. 5) pg/ml vs 76. 1 ( 39. 4-112. 0) pg/ml, Z =-10. 114, P < 0. 001]. In the CHB patients who did not receive antiviral therapy, serum IFN-λ3 level was negatively correlated with log HBV DNA ( r =-0. 621, P < 0. 001) . The HBeAg-negative CHB patients had a significantly higher serum IFN-λ3 level than the HBeAg-positive CHB patients [16. 4 ( 9. 0-31. 3) pg/ml vs 8. 7 ( 2. 9-23. 2) pg/ml, Z =-2. 205, P = 0. 02]. The patients who received antiviral therapy with adefovir dipivoxil had a significantly higher serum IFN-λ3 level than those who were treated with entecavir, tenofovir, telbivudine, or lamivudine ( P < 0. 05) . In vitro experiment showed that there was no significant increase in serum IFN-λ3 level in the supernatant of PBMCs treated with NAs. Conclusion CHB patients have a significantly lower serum IFN-λ3 level than healthy individuals, and the CHB patients receiving antiviral therapy with adefovir dipivoxil have a relatively high serum IFN-λ3 level.
- hepatitis B, chronic /
- interferons

HTML全文

参考文献(22)

[1]WANG WJ, XIE Q.Challenges and strategies of antiviral therapy for chronic hepatitis B-how to achieve the maximization of clinical cure?[J].J Clin Hepatol, 2017, 33 (8) :1415-1418. (in Chinese) 王伟静, 谢青.慢性乙型肝炎抗病毒治疗的挑战与策略---如何实现临床治愈最大化[J].临床肝胆病杂志, 2017, 33 (8) :1415-1418.

[2]PAPATHEODORIDIS GV, LAMPERTICO P, MANOLAKOPOU-LOS S, et al.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos (t) ide therapy:A systematic review[J].J Hepatol, 2010, 53 (2) :348-356.

[3]WONG LH, CHAN LY, MAK WH, et al.Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis[J].Hepatology, 2013, 58 (5) :1537-1547.

[4]TRPO C, CHAN HL, LOK A.Hepatitis B virus infection[J].Lancet, 2014, 384 (9959) :2053-2063.

[5]MARCELLIN P, LAU GK, BONINO F, et al.Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBe Ag-negative chronic hepatitis B[J].N Engl JMed, 2004, 351 (12) :1206-1217.

[6]QI X.Peginterferon alfa-2a, lamivudine, and the combination for HBe Ag-positive chronic hepatitis B[J].N Engl J Med, 2005, 352 (26) :2682-2695.

[7]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:A 2015 update[J].JClin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[8]HRUSKA M, WANG X, CHAN P, et al.Derivation of phase 3dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2:Exposure-response analyses for efficacy and safety variables[J].J Clin Pharmacol, 2015, 55 (1) :73-80.

[9]BOLEN CR, DING S, ROBEK MD, et al.Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression[J].Hepatology, 2014, 59 (4) :1262-1272.

[10]LIAO Y, LI Y, CAI B, et al.Lack of association between IL-28Bpolymorphisms and spontaneous virus clearance in HBV patients[J].Clin Infect Dis, 2013, 75 (9) :409-417.

[11]SHI X, CHI X, PAN Y, et al.IL-28B is associated with outcomes of chronic HBV infection[J].Yonsei Med J, 2015, 56 (3) :625-633.

[12]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis B:A 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[13]MURATA K, ASANO M, MATSUMOTO A, et al.Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues:A new potential target for HBV infection[J].Gut, 2018, 67 (2) :362-371.

[14]ZOU HX, WANG JH, CUI HL, et al.The relativity study between abnormal serum markers of hepatitis B and HBV-DNA[J].Int J Virol, 2017, 27 (4) :239-242. (in Chinese) 邹红霞, 王金环, 崔海玲, 等.乙型肝炎异常血清学诊断模式与HBV-DNA载量的相关性研究[J].国际病毒学杂志, 2017, 27 (4) :239-242.

[15] GONG Q.Clinical significance of combined determination of HBV-DNA、five indicators for hepatitis B and liver function parameters in patients with chronic hepatitis B[J].World Clin Med, 2017, 11 (7) :230. (in Chinese) 龚蔷.HBV-DNA、乙肝两对半和肝功能的联合检测对慢性乙肝患者的临床意义[J].世界临床医学, 2017, 11 (7) :230.

[16]ABUSHAHBA W, BALAN M, CASTANEDA I, et al.Antitumor activity of type I and type III interferons in BNL hepatoma model[J].Cancer Immunol Immunother, 2010, 59 (7) :1059-1071.

[17]ISOGAWA M, TANAKA Y.The Immunobiology of hepatitis Bvirus infection[J].Hepatol Res, 2015, 45 (2) :179-189.

[18]KOTENKO SV.IFN-λs[J].Curr Opin Immunol, 2011, 23 (5) :583-590.

[19]SOMMEREYNS C, PAUL S, STAEHELI P, et al.IFN-lambda (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo[J].PLo S Pathog, 2008, 4 (3) :e1000017.

[20]van der MOLEN RG, SPRENGERS D, BIESTA PJ, et al.Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV[J].Hepatology, 2010, 44 (4) :907-914.

[21]YOU J, CHEN J, YE QX, et al.Efficacy of add-on adefovir dipivoxil at week 12/24 in HBe Ag-positive chronic hepatitis Bpatients during PEG-IFN-αtherapy[J].J Clin Hepatol, 2016, 32 (4) :687-690. (in Chinese) 游佳, 陈靖, 叶巧霞, 等.聚乙二醇干扰素α加用阿德福韦酯治疗HBe Ag阳性慢性乙型肝炎的效果观察[J].临床肝胆病杂志, 2016, 32 (4) :687-690.

[22]XIE Q, ZHOU H, BAI X, et al.A randomized, open-label clinical study of combined pegylated interferon alfa-2a (40KD) and entecavir treatment for hepatitis B"e"antigenpositive chronic hepatitis B[J].Clin Infect Dis, 2014, 59 (12) :1714-1723.

施引文献

资源附件(0)

访问统计